Dr. Priyom Bose

Feature Writer

B.Sc. Botany, M.Sc. Plant Biology and Biotechnology, Ph.D. Plant Biology and Biotechnology

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Articles from Priyom

Presidential advisory by the American Heart Association: connecting cardiovascular, kidney, and metabolic health

The interplay among chronic kidney disease, metabolic risk factors, and the cardiovascular system.

11 Oct 2023

A novel drug reduces the monthly frequency of seizure in adults with focal epilepsy

The effect of a novel Kv7.2/Kv7.3 potassium channel opener XEN1101 in reducing monthly seizure frequency in adults.

11 Oct 2023

Did the COVID-19 pandemic increase drunkness among people with a history of alcohol use disorder?

How COVID-19-related stressors altered drunkenness frequency.

10 Oct 2023

Discovery of a novel therapeutic target for pancreatic cancer

A novel amino acid transporter-based therapeutic target for pancreatic ductal adenocarcinoma (PDAC).

10 Oct 2023

Can your body odor protect you against disease?

Whether body odor is protective against diseases.

9 Oct 2023

Precision medicine for gestational diabetes management

Precision markers to predict effective lifestyle and pharmacological interventions to manage Gestational Diabetes Mellitus.

9 Oct 2023

Is HPV infection a hidden risk factor for prostate cancer?

In a comprehensive meta-analysis published in Scientific Reports, researchers unveil a significant link between human papillomavirus (HPV) infection and increased risk of prostate cancer, highlighting the importance of considering normal prostate tissues over benign prostatic hyperplasia (BPH) as controls for more accurate conclusions.

8 Oct 2023

Nirmatrelvir and ritonavir combo cuts COVID-19 risks for high-vulnerability groups

Nirmatrelvir and ritonavir treatment significantly reduces the risk of hospitalization and death from COVID-19 in high-risk individuals, according to a recent JAMA Network Open study. However, the treatment's efficacy varied based on the degree of vulnerability, emphasizing tailored approaches for different risk groups.

8 Oct 2023

Unlocking the future of cancer care: Overcoming challenges in personalized neoantigen vaccine development

Challenges associated with the development and design of neoantigen cancer vaccines.

5 Oct 2023

The metabolic effects of endocrine therapy on diabetes mellitus in breast cancer survivors

Researchers discuss the history of endocrine therapies, highlights their adverse metabolic effects, and emphasizes the need for better biomarkers of diabetes.